Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Innovative macrophage therapies to transform treatment paradigm of solid tumors

Project description

Engineering macrophages to fight solid tumours

Solid tumours account for 90 % of all cancers. Current cell therapies remain largely ineffective as immune cells typically struggle to infiltrate them. Macrophages – innate immune cells naturally recruited into tumours – are a promising solution but their clinical use has been hampered by their rapid activity loss, poor expansion in culture and vulnerability to the tumour’s immunosuppressive environment. By reactivating self-renewal mechanisms, researchers have generated macrophages that overcome these challenges. The EIC-funded STEMPhage project aims to translate this breakthrough discovery into a viable therapy. STEMPhage will establish clinical-grade production, elucidate mechanisms of action and develop standardised efficacy assays. Simultaneously, it will build the foundations for a spin-off to deliver a transformative off-the-shelf cancer treatment.

Objective

The STEMPhage project at TU Dresden aims to develop a pioneering macrophage-based therapy for the treatment of solid tumors. Solid tumors account for 90% of all cancers and remain largely inaccessible to current cell therapies, as T cells, for example, often fail to effectively infiltrate them. Macrophages, by contrast, are innate immune cells that are naturally recruited into tumors, where they can not only destroy tumor cells directly but also activate other immune cells to mount a coordinated anti-tumor response. Until now, however, the clinical application of macrophages has been limited by their rapid loss of activity, inability to expand in culture, and susceptibility to immunosuppressive signals within the tumor microenvironment. Through decades of research led by Humboldt Professor Michael Sieweke, the STEMPhage team has overcome these barriers. By reactivating intrinsic self-renewal mechanisms, the team has generated so-called xMACx macrophages that can be robustly expanded in culture and retain potent anti-tumor activity in immunosuppressive tumor environments. The potential to produced large quantities of macrophages makes them available as an off-the-shelf therapy with stable and durable anti-tumor effects. This breakthrough has the potential to fundamentally transform cancer treatment. Within the project, GMP-compliant production of xMACx will be established, their mechanisms of action elucidated, and standardized efficacy assays developed. In parallel, the team will create the business structures and financial foundations for a spin-off to translate this technology towards clinical application and attract strategic investment. The EIC funding will secure STEMPhage’s technological lead and laying the groundwork for a radically new, innovative cancer therapy of major societal and economic impact.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2025-TRANSITIONOPEN

See all projects funded under this call

Coordinator

TECHNISCHE UNIVERSITAET DRESDEN
Net EU contribution
€ 2 499 935,06
Address
HELMHOLTZSTRASSE 10
01069 Dresden
Germany
Region
Sachsen Dresden Dresden, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data